Related Experiment Video

Updated: May 6, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective

Nicolas Girard1

  • 1Department of Respiratory medicine, Thoracic Oncology, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University, Lyon, France +33 47 235 7652 +33 47 235 7653 nicolas.girard@chu-lyon.fr.

Expert Review of Anticancer Therapy
|October 19, 2013
PubMed

Insights

Antiangiogenic agents improve outcomes for advanced non-small-cell lung cancer patients. Newer drugs show promise in second-line treatment, with ongoing research for better patient selection and new approvals.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Antiangiogenic agents are crucial in managing advanced non-small-cell lung cancer (NSCLC) alongside chemotherapy.
  • Bevacizumab is established for first-line therapy, while nintedanib shows efficacy in the second-line setting.

Purpose of the Study:

  • To review recent advancements in antiangiogenic treatments for advanced NSCLC.
  • To focus on clinical practice relevance and potential new drug approvals.
  • To discuss the role of biomarkers in patient selection.

Main Methods:

  • Literature review of recent clinical trial data and research findings.
  • Analysis of treatment outcomes and efficacy of antiangiogenic agents.
  • Discussion of current and emerging therapeutic strategies in thoracic oncology.

Main Results:

  • Antiangiogenic agents demonstrate significant activity in both first- and second-line NSCLC treatment.
  • Nintedanib has shown notable efficacy in the second-line setting.
  • Further research is needed to identify predictive biomarkers for patient selection.

Conclusions:

  • Antiangiogenic therapy is a valuable approach in advanced NSCLC management.
  • The development of these agents serves as a model for thoracic oncology.
  • Improved patient outcomes are anticipated with continued advancements and biomarker discovery.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619